Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

NCT01646021 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Temsirolimus

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]